Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalized dosing may improve stem cell transplant survival in blood cancer patients

NCT ID NCT07717164

Not yet recruiting Knowledge-focused Sponsor: Miltenyi Biomedicine GmbH Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study compares survival and other outcomes in patients with acute leukemia or myelodysplastic syndrome who received a stem cell transplant with a personalized dose of an immune-suppressing drug (r-ATG) to similar patients from a large registry who received standard treatments. The goal is to see if the personalized approach leads to better survival and fewer complications. Researchers will analyze data from a previous phase 2 study and compare it to registry data from patients who received standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
personalized rabbit anti-thymocyte globulin (r-ATG) dosing with CD34-selected allogeneic hematopoietic cell transplant
What this could lead to
If successful, this could show that personalized r-ATG dosing improves survival and reduces complications in stem cell transplants for blood cancers.
What could go wrong
This is an observational comparison using historical registry data, not a randomized trial, so results may be influenced by differences between groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE B LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia myelodysplastic syndrome myelodysplastic syndrome with excess blasts precursor B-cell acute lymphoblastic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALL (ACUTE B-LYMPHOBLASTIC LEUKEMIA) AML (ACUTE MYELOID LEUKEMIA) MDS (MYELODYSPLASTIC SYNDROME)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Memorial Sloan Kettering Cancer center

    New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.